Literature DB >> 14660268

Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab.

F Rongioletti1, M Borenstein, Robert Kirsner, Francisco Kerdel.   

Abstract

This report describes the case of a patient with erythrodermic psoriasis who had failed all previous therapies and been hospitalized numerous times over a 12-year period that responded dramatically to treatment with infliximab. The potential utility of infliximab as a therapeutic alternative for erythrodermic psoriasis is discussed.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14660268     DOI： 10.1080/09546630310010895

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN： 0954-6634            Impact factor:   3.359


  5 in total

1.  Emergencies in Dermatology : Acute Skin Failure.

Authors:  S S Vaishampayan; Y K Sharma; A L Das; R Verma
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 2.  Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances.

Authors:  Shuai Shao; Gang Wang; Emanual Maverakis; Johann E Gudjonsson
Journal:  Drugs       Date:  2020-04       Impact factor: 9.546

3.  A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2.

Authors:  Bruce E Strober; Jennifer Clay Cather; David Cohen; Jeffrey J Crowley; Kenneth B Gordon; Alice B Gottlieb; Arthur F Kavanaugh; Neil J Korman; Gerald G Krueger; Craig L Leonardi; Sergio Schwartzman; Jeffrey M Sobell; Gary E Solomon; Melodie Young
Journal:  Dermatol Ther (Heidelb)       Date:  2012-03-30

4.  Erythrodermic psoriasis: pathophysiology and current treatment perspectives.

Authors:  Rasnik K Singh; Kristina M Lee; Derya Ucmak; Merrick Brodsky; Zaza Atanelov; Benjamin Farahnik; Michael Abrouk; Mio Nakamura; Tian Hao Zhu; Wilson Liao
Journal:  Psoriasis (Auckl)       Date:  2016-07-20

Review 5.  An evolution in switching therapy for psoriasis patients who fail to meet treatment goals.

Authors:  Francisco Kerdel; Martin Zaiac
Journal:  Dermatol Ther       Date:  2015-08-10       Impact factor: 2.851
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.